No announcement yet.

Stem Cell Articles

  • Filter
  • Time
  • Show
Clear All
new posts

    lol manouli, slow down i cant read that fast!


      I liked the article regarding breast augmentation via stem cells.
      Put stem cell research in the mainstream like that and.. who knows?
      We could get fixed up by a couple boobs.

      Sounds nice to me!
      Rick Brauer or just call me - Mr B


        Originally posted by Ivica Rod
        lol manouli, slow down i cant read that fast!
        Hi Ivica, today they are posting many stem cell articles. I just don't want you guys to miss anything. Too bad not for spinal cord stem cell trials. I am still hopefull. We need money money money.

        Blood-Forming Stem Cells Cultured from Human Fat Tissue


        Investigators say a patient's adipose tissue may be an alternate source for life-saving haematopoietic stem cell transplants.

        Complete Article
        18 Jul 2007
        Researchers at the University of Pittsburgh School of Medicine have successfully isolated and cultured human haematopoietic stem cells from fat, or adipose, tissue, suggesting that they have found another important source of cells for reconstituting the bone marrow of patients undergoing intensive radiation therapy for blood cancers. They are presenting this ground-breaking research at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) North American Chapter meeting being held June 13 to 16 at the Westin Harbor Castle conference centre in Toronto.

        Adipose tissue has the ability to rapidly expand or contract in accordance with nutritional constraints. In so doing, it requires rapid adjustment in its blood supply and supporting connective tissue, or stroma. Based on previous reports that the "stromal vascular" fraction of adipose tissue contains stem cells that give rise to pericytes - cells surrounding small blood vessels - the University of Pittsburgh School of Medicine researchers, led by Albert D. Donnenberg, Ph.D., professor and director of the Haematopoietic Stem Cell Laboratory, University of Pittsburgh Cancer Institute, isolated the stromal vascular fraction from human adipose tissue and expanded these cells by growing them in a specialized blood-culturing medium for 21 to 42 days.

        Using a cell-sorting method known as flow cytometry, the researchers detected a broad spectrum of blood-forming, or haematopoietic, cells among the cultured cells at varying stages of differentiation. In particular, they observed both early and mature red blood cells. Moreover, they detected CD34+ cells at approximately the same frequency as is present in freshly isolated bone marrow. In bone marrow, CD34+ expression indicates the presence of progenitor cells which give rise to all of the different types of blood cells.



          Stem cell trial gets $2M shot in arm

          Tuesday, 8:00 p.m.: Hope for MS patients

          By ALLAN WIGNEY, Sun Media

          In response to “unexpected” positive results, a local research facility conducting a bone marrow stem cell transplant therapy trial has been awarded additional funding.

          The Multiple Sclerosis Society of Canada announced Tuesday that the Ottawa Health Research Institute, a University of Ottawa-affiliated arm of the Ottawa Hospital, will receive $2.4 million over five years to continue and further develop the trial begun in October 2000.

          The procedure, which early on resulted in one death and carries potentially serious side effects, involves employing a patient’s bone marrow cells to replace a diseased immune system with a new, purified one.

          A similar procedure has attained positive results in cancer patients, but has rarely been applied to the treatment of autoimmune diseases such as MS, an often-debilitating, chronic condition affecting the brain and spinal cord.

          More than two dozen patients with rapidly progressive disease were selected for the initial stages of the trial; 18 have received the transplant therapy.




            -17 July 2007



              Thanks Doc Wise

              thanks for your continued interest and contributions to this site.

              May i ask, as we do know there is NO DAMN MONEY FOR THIS SPINAL CORD INJURY research, surely there has to be a way to find someone somewhere that can fund that will lead on other people to follow suit and start a chain reaction.

              Look at how many people have spinal cord injuries and you are telling me that no one of these people know some wealthy/influential people???
              That is what i find hard to believe.

              C'mon CC members, lets get our asses into gear and start getting the DAMN money to get you all a better quality of life!!!!
              How does a blade of grass thank the sun?




                Exclusive by Richard Smith 18/07/2007

                THIS baby scan shows the unborn tot who it is hoped will give his big brother the gift of life.

                Controversial stem-cell therapy is the only hope for 20-year-old Michael Emms, who has been struck down by motor neurone disease.

                And the baby, due to be born at the end of September and already named Rhys, may be the perfect donor.

                Dad Julian, 41, said yesterday: "It would be just amazing if little Rhys saved Michael. We are all hoping Rhys will be our miracle baby.

                "The prospect of the treatment has cheered Michael up no end. It's something for him to focus on, a light at the end of the tunnel."

                Vital stem cells will be taken from the baby's umbilical cord when Julian's fiancee Joanna Stanley gives birth.

                The cells will then be frozen and flown to a clinic in America where they will be implanted into Michael's spinal cord.

                Mum-to-be Joanna, 27, said: "Mike's best chance is to have cells from a donor who is a close genetic match. The best he is going to get is from his brother, even though he is not yet born."

                She was six-weeks pregnant when she read on the internet about the treatment for motor neurone disease victims and realised immediately it could be Michael's only chance for survival.

                She added: "To get a match otherwise could take three or four years and Michael doesn't have years, he only has months.

                "Nothing's certain about the treatment, but even a one per cent chance could mean everything."

                A year ago Michael, of Caerwent, near Newport, Monmouthshire, was an active young man playing football and working at a DIY warehouse.

                But when crippling pain spread through his body last June specialists diagnosed motor neurone disease.




                  CellCyte Executives Highlight Plans for Breakthrough Stem Cell-Enabling Therapeutic Products, Devices Providing Innovative Solutions in Organ Repair

                  July 18, 2007: 09:15 AM EST

                  KIRKLAND, Wash., July 18 /PRNewswire-FirstCall/ -- Gary A. Reys, Chairman, President and CEO of CellCyte Genetics Corporation and Theresa A. Deisher, Vice President of Research and Development of the Bothell, Washington-based biotechnology firm recently gave their views about moving quickly into a global leadership position in the emerging field of regenerative medicine with the company's breakthrough stem cell-enabling therapeutic products and devices that are providing innovative solutions to critical barriers in stem cell organ repair in a Q & A interview published in The Wall Street Transcript (

                  In bringing perspectives to The Wall Street Transcript, an independent weekly investment publication for serious investors, Mr. Reys said CellCyte Genetics' focus since it was formed in 2003 has been "to acquire technologies that were already patented or had patents pending covering breakthrough technology discoveries that were far down the research and development pathway. This approach would mitigate many of the risks associated with startup companies and allow CellCyte to take these products to market at a much more rapid pace. We are focused on basically (adult) stem cell delivery, not embryonic stem cells."

                  Mr. Reys also noted, "CellCyte Genetics' business platform is now well understood by the investment communities as we are the first company in the stem cell sector to offer a true blockbuster product platform and revenue model. It is a very sound platform, one-of-a-kind in the world. We are the leader in non-invasive cell (stem-cell) delivery, with a true biologic product supplied in a vial; 'the pill in the bottle,'" he said.




                    Manoulli, I think that it is great to have a topic for stem cell articles.



                      Originally posted by Wise Young
                      Manoulli, I think that it is great to have a topic for stem cell articles.

                      Dr. Young, it was your idea. You are always do the right thing.

                      Thank you, manouli


                        Wednesday July 18, 2007

                        German Ethics Council Narrowly Recommends Removing Ban on Embryonic Stem Cell Research

                        By Peter J. Smith

                        BERLIN, July 18, 2007 ( - The National Ethics Council, the body charged with advising the German government on medical ethics, narrowly recommended that the law banning embryonic stem-cell research be gutted of its most important protections on Monday. The recommendation sets the stage for the Parliament to consider revising the law later this autumn.

                        In a narrow 14 - 10 vote, the NEC voted in favour of abolishing the law's cut-off date that prohibits German scientists from working on any stem-cell lines derived from human embryos killed after January 1, 2002. The 2002 law was passed in an effort to discourage foreign laboratories from making and marketing embryonic stem-cell lines to German scientists.

                        The NEC proposal would abolish the cut-off date and set up an authority to test each case individually. According to the minority this would effectively "hollow out the stem cell law" depriving the law of any real force.

                        Horst Dreier, speaking for the NEC majority, argued for liberalizing the stem-cell laws, saying, "If the current rules remain, German science will be hopelessly sidelined". The majority said that a change in the law should guarantee that manufacturers do not make a profit and should end penalties for scientists involved in international projects using embryonic stem cells.

                        However, the minority report protested against the majority's proposal, pointing out that no cures have resulted from embryonic stem cell research and therapies based on it are unlikely to be developed in the foreseeable future.




                          MS Society Announces 2.4 Million Dollars To Continue Ottawa Bone Marrow Stem Cell Transplant Trial

                          19 Jul 2007

                          The Multiple Sclerosis Society of Canada announced a 2.4 million dollars grant to continue a closely-watched clinical trial involving an experimental bone marrow stem cell transplant therapy. The trial is being conducted by a team of Canadian MS specialists led by Dr. Mark Freedman and Dr. Harry Atkins in Ottawa.

                          "The aim of the study was to see if this treatment protocol could halt deterioration in a group of MS patients with rapidly progressive disease," says Jon Temme, vice president of client services and research for the MS Society. "Currently, the majority of the 18 patients have stabilized or improved, and the focus of this second phase of the trial will be to determine if this stabilization can be maintained."

                          Multiple sclerosis is a chronic, often disabling disease of the brain and spinal cord. Between 55,000 and 75,000 Canadians have MS making it the most common neurological disease of young adults in Canada. Most people with MS are diagnosed between the ages of 15 and 40.

                          MS symptoms are unpredictable and vary greatly from person to person but can include: double or blurred vision; extreme fatigue; loss of balance; stiffness of muscles; speech problems; bladder and bowel problems; and even partial or complete paralysis.

                          "The idea behind this clinical trial is to replace the diseased immune system with a new one derived from the patient's own bone marrow stem cells," explains Dr. Harry Atkins, a scientist at the Ottawa Health Research Institute, bone marrow transplant specialist at the Ottawa Hospital, and assistant professor at the University of Ottawa. "First we purify and freeze the patient's stem cells, then we use strong chemotherapy to destroy their existing immune system, and then we transplant the purified stem cells back into the patient. It takes time, but eventually these stem cells will form a completely new immune system - one that does not attack the brain and spinal cord - we hope."

                          A similar procedure has been used to treat certain types of blood cancer for more than 25 years, but applying the procedure to treat autoimmune diseases such as MS is novel.

                          "We hoped that this therapy would halt or slow the progression of MS, and in the patients examined so far, it seems to have worked," says Dr. Mark Freedman, a senior scientist at the Ottawa Health Research Institute, director of the Ottawa Hospital MS Clinic, and professor at the University of Ottawa. "In addition, some patients have experienced substantial improvements in their ability to see and walk. This was unexpected, and it suggests the exciting possibility that the therapy may be contributing to some sort of repair or regeneration. With this funding, we can investigate this further."




                            Thursday, July 19, 2007

                            Gov. to file stem cell center bill

                            Mello to address full Legislature

                            By John J. Monahan TELEGRAM & GAZETTE STAFF

                            BOSTON— Gov. Deval L. Patrick is expected to file legislation to start up a planned $1 billion, 10-year state investment in life sciences research as soon as today, when he joins legislative leaders in honoring University of Massachusetts Medical School Nobel Prize-winning researcher Craig C. Mello at a special joint session of the Legislature.

                            The unusual joint session of the House and Senate is aimed at honoring Mr. Mello’s breakthrough research on gene therapy that earned him and a fellow researcher the Nobel Prize for physiology or medicine, and at giving lawmakers a chance to hear his views on ways to develop life sciences in Massachusetts.

                            Mr. Mello and Andrew Fire, formerly of the Carnegie Institution, received the award last year for their discovery of RNAi gene mechanisms that allow specific genes to be silenced or turned off, to produce biological results that hold promise for new treatments of leukemia, cancer, HIV/AIDS and other diseases.

                            Mr. Mello will address the joint session of the Legislature at the event that begins at 1 p.m. The session will include statements from the governor, House speaker and Senate president.

                            In May, Mr. Patrick, with Mr. Mello at his side, announced his plans for a combination of state bond funds, tax credits and other financing totaling an estimated $100 million annually over the next 10 years to advance Massachusetts as a world leading research center for stem cell and RNAi therapies and regenerative medicine.

                            Officials in the governor’s office yesterday would not confirm the funding legislation was ready for submission, but at least portions of the proposal were expected to be offered to the Legislature in time for announcements at the event.

                            The proposals call for development of major new research facilities at the University of Massachusetts Medical School, including the establishment of a first-in-the-nation stem cell bank to store and distribute stem cell lines from the state’s major stem cell research facilities to researchers from around the world. It also would provide funding for other genetic research facilities at the Worcester medical school campus.
                            Together those facilities are expected to cost more than $100 million, with initial estimates for the stem cell bank and stem cell research center pegged at $66 million. Also in the works is an RNAi therapeutics center that got a major boost when Mr. Mello’s research was recognized by the Nobel Prize Committee.




                              Stem cell scientists flock to the northwest

                              The northwest is hosting an international stem cell conference this week, with experts flying in from as far afield as Singapore and Toronto.

                              Held at the University of Manchester and chaired by Lord Naren Patel, chair of the UK National Stem Cell Network, the convention will last three days and will culminate in a question-and-answers event.

                              On Wednesday, an audience of scientists will be invited to submit queries on important and contentious issues that face stem cell researchers.




                                Hematopoietic Stem Cells VI

                                Edited by: Lothar Kanz, University of Tübingen, Tübingen, Germany; Katja C. Weisel, University of Tübingen, Tübingen, Germany; John E. Dick, University of Toronto, Toronto, Ontario, Canada; Willem E. Fibbe, Leiden University Medical Center, Leiden, the Netherlands

                                Stem cell research holds great promise for therapeutic applications. This rapidly advancing field is the focus of the biennial international symposium and workshop whose proceedings are contained within this volume.